false
0002030617
0002030617
2026-02-26
2026-02-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 26, 2026
Picard Medical, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-42801 |
|
86-3212894 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
1992 E Silverlake
Tucson AZ, 85713 |
| (Address of principal executive offices, including zip code) |
Registrant’s telephone number, including
area code: (520) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
PMI |
|
The NYSE American, LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
|
Item 7.01. |
Regulation FD Disclosure. |
On
February 26, 2026, Picard Medical, Inc. (the “Company”) issued a press release announcing that the Company will participate
in the “Hands-On Training Day” at the Technology and Heart Failure Therapeutics 2026 conference to be held on March 1, 2026,
in Boston, Massachusetts. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The
information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation
language in such filing.
| |
Item 9.01. |
Financial Statements and Exhibits. |
The following exhibits are
being filed herewith:
| Exhibit No. |
|
Description |
| 99.1 |
|
Picard Medical, Inc. Press Release dated February 26, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Picard Medical, Inc. |
|
| |
|
| By: |
/s/ Patrick NJ Schnegelsberg |
|
| |
Name: |
Patrick NJ Schnegelsberg |
|
| |
Title: |
Chief Executive Officer |
|
Dated: February 26, 2026
Exhibit 99.1
Picard Medical / SynCardia
to Participate in Inaugural “Hands-On Training Day” at the Technology and Heart Failure Therapeutics Conference
– Training will consist
of an interactive clinical education program highlighting real world application of the SynCardia Total Artificial Heart in advanced heart
failure patients –
Tucson, Ariz. February 26, 2026 - Picard Medical, Inc. (NYSE
American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s
first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the inaugural “Hands-On
Training Day” at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston on March 1st
2026.
This interactive, case-based program hosted for the first time at the
conference will bring together leading clinicians and innovators to advance education in temporary and durable mechanical circulatory
support, hemodynamic monitoring, and the management of cardiogenic shock. Through hands-on training and real-world clinical scenarios,
the program is designed to strengthen multidisciplinary collaboration among practitioners and improve patient outcomes in advanced heart
failure.
Stephen Zamojski, Head of Global Sales and Clinical Education at SynCardia
Systems LLC, commented, “As adoption of total artificial heart therapy continues to expand, education and hands-on familiarity are
critical. By engaging directly with the technology in a collaborative setting, clinicians can deepen their understanding of how the SynCardia
Total Artificial Heart supports patients through the most advanced stages of heart failure. Our participation in the inaugural Hands-On
Training Day at THT 2026 follows the successful SynCardia Training Village held in Houston earlier this week and reflects a key component
of our commercial expansion strategy. We remain focused on building strong clinical partnerships, expanding global awareness, and ensuring
that leading heart failure centers are equipped to deliver this life-saving therapy.”
Picard Medical / SynCardia is proud to support this important educational
initiative and looks forward to engaging with physicians, fellows, and multidisciplinary clinical teams as it continues to expand global
awareness and adoption of total artificial heart therapy. Senior Clinical Specialists, Lauren Wallace, and Skyler Peffly, will lead the
training, offering participants direct, hands-on interaction with the Companion 2 Driver, the Freedom Portable Driver, and the SynCardia
Total Artificial Heart.
Attendees will rotate through interactive stations in a small group
setting designed to foster focused instruction, peer exchange, and active problem solving. The session will incorporate real-world clinical
scenarios and guided discussion to support clinical decision-making, device management, and patient care best practices in complex cases
of advanced biventricular heart failure.
About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international
conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored
by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share
the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart
failure. The multidisciplinary program features cutting-edge scientific sessions, case-based discussions, and hands-on training designed
to foster collaboration and improve patient outcomes. For more information, visit https://www.thtmeeting.com/about-tht.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC
(“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology
for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”),
an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by
both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With
more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and
extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com
or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve
risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are
subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly
disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on
which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection
with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
